MDMA, administered in controlled doses (75mg to 180mg) during supervised sessions, significantly reduces depressive symptoms, even in cases resistant to conventional treatments. Therapeutic effects include rapid mood improvement, increased empathy, and reduced emotional isolation, with benefits sustained for months. Adverse events, such as tachycardia and nausea, were mild and transient. These findings suggest MDMA is a viable alternative for treating depressive disorder, especially refractory cases, though further studies are needed to validate its efficacy, safety, and clinical feasibility, and to overcome regulatory and logistical challenges.
Post-Traumatic Stress Disorder (PTSD) involves distress after a traumatic event, and current treatments have limitations. MDMA, a psychedelic amphetamine, shows promise for enhancing psychotherapy. This integrative literature review of 16 articles from 2018-2024 examined MDMA-assisted psychotherapy for PTSD, covering phase 2 and 3 clinical trials, effects on therapeutic alliance, fear extinction, memory reconsolidation, and neurobiological systems. Results suggest MDMA improves therapeutic outcomes, but more research is needed on its exact neurobiological mechanisms and long-term effects.